Edmondo Robinson named chief digital innovation officer at Moffitt

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Edmondo Robinson was named senior vice president and chief digital innovation officer at Moffitt Cancer Center.

Robinson, who brings over 16 years of clinical and technology experience to Moffitt, will oversee Moffitt’s portfolio of digital innovation, including the development and commercialization of health products, tools and technology. With this new role, Moffitt aims to create and test new services, programs, partnerships and technologies that leverage digital innovations, while challenging the status quo to reduce the cost of care, improve quality, increase access to care and enhance the patient experience.

Previously, Robinson was the chief transformation officer and senior vice president of consumerism at ChristianaCare, where he was responsible for the transformation of health care delivery to advance population health initiatives and the move from volume-based to value-based care.

Robinson is an associate professor of medicine at Thomas Jefferson University’s Sidney Kimmel Medical College. He holds a medical degree from UCLA; an MBA from The Wharton School of the University of Pennsylvania; and a master’s degree in health policy research also from the University of Pennsylvania.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login